Income Taxes

9 Months Ended

May 26, 2023

Income Tax Disclosure [Abstract]

Income Taxes

Income Taxes

	Three Months Ended				Nine Months Ended
	May 26, 2023		May 27, 2022		May 26, 2023		May 27, 2022
Income (loss) before taxes	$	(17,375)	$	29,649	$	(35,663)	$	68,660
Income tax provision	6,702		5,154		9,876		20,495

Interim income tax provision includes a provision for federal, state and foreign taxes based on the annual estimated effective tax rate applicable to us and our subsidiaries, adjusted for certain discrete items which are fully recognized in the period they occur. We have historically determined our interim income tax provision (benefit) by applying the annual estimated effective income tax rate expected to be applicable for the full fiscal year to the income (loss) before taxes for the interim period. In determining the full year estimate, we do not include the estimated impact of unusual and/or infrequent items, which may cause significant variations in the customary relationship between income tax provision (benefit) and income (loss) before taxes. Additionally, our income tax provision (benefit) is subject to volatility and could be impacted by changes in our geographic earnings, non-deductible stock based compensation and certain tax credits.

Income tax provision for the third quarter of 2023 increased by $1.5 million as compared to the same period in the prior year, primarily due to an increase in U.S. profits. For tax years beginning on or after January 1, 2022, the Tax Cuts and Jobs Act of 2017 eliminates the option to deduct research and development expenditures, as defined under IRC Section 174, in the year incurred. Instead, taxpayers are required to amortize such expenditures over five years if incurred in the U.S. and over fifteen years if incurred in a foreign jurisdiction. Due to this change, we expect to incur U.S. taxes despite historical net operating losses and credit carryforwards. Income tax provision for the first nine months of 2023 decreased by $10.6 million as compared to the same period in the prior year, primarily due to current year losses in certain of our foreign operations, offset by increase in U.S. taxable profits.

As of May 26, 2023 and August 26, 2022, we had a full valuation allowance for net deferred tax assets associated with our U.S. operations, based on an analysis of positive and negative evidence, including analyzing three-year cumulative pre-tax income or loss, projections of future taxable income and other quantitative and qualitative information. We intend to maintain a full valuation allowance on our U.S. net deferred tax assets until there is sufficient positive evidence to support the reversal of all or some portion of the valuation allowance. Due to improvements in our U.S. operating results over the past three years, we believe there is a reasonable possibility that, within the next 12 months, sufficient positive evidence may become available to allow us to reach a conclusion that a significant portion of the valuation allowance will no longer be needed. Release of the valuation allowance would result in the recognition of certain deferred tax assets and a decrease to income tax expense in the period the valuation allowance is released. However, the exact timing and amount of the valuation allowance release are subject to change based on the level of our U.S. profitability.

Determining the consolidated income tax provision (benefit), income tax liabilities and deferred tax assets and liabilities involves judgment. We calculate and provide for income taxes in each of the tax jurisdictions in which we operate, which involves estimating current tax exposures as well as making judgments regarding the recoverability of deferred tax assets in

each jurisdiction. The estimates used could differ from actual results, which may have a significant impact on operating results in future periods.